menu
    • menu
    [{"orgOrder":0,"company":"Viatris","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Etanercept","moa":"TNF alpha","graph1":"Immunology","graph2":"Phase III","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Viatris \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Viatris \/ Not Applicable"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Etanercept","moa":"TNF alpha","graph1":"Dermatology","graph2":"Approved","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Merck & Co \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Merck & Co \/ Not Applicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Etanercept","moa":"TNF alpha","graph1":"Immunology","graph2":"Phase I","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sorrento Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sorrento Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Sorrento Therapeutics","sponsor":"4P Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Etanercept","moa":"TNF","graph1":"Immunology","graph2":"Phase I","graph3":"Sorrento Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sorrento Therapeutics \/ 4P Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Sorrento Therapeutics \/ 4P Therapeutics"},{"orgOrder":0,"company":"Biogen","sponsor":"Samsung Biologics","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Divestment","leadProduct":"Etanercept","moa":"TNF alpha","graph1":"Immunology","graph2":"Approved","graph3":"Biogen","amount2":2.2999999999999998,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":2.2999999999999998,"dosageForm":"Subcutaneous Injection","sponsorNew":"Biogen \/ Samsung Biologics","highestDevelopmentStatusID":"12","companyTruncated":"Biogen \/ Samsung Biologics"},{"orgOrder":0,"company":"Samsung Bioepis","sponsor":"Samsung Biologics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SOUTH KOREA","productType":"Large molecule","year":"2022","type":"Acquisition","leadProduct":"Etanercept","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Samsung Bioepis","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Samsung Bioepis \/ Samsung Biologics","highestDevelopmentStatusID":"12","companyTruncated":"Samsung Bioepis \/ Samsung Biologics"},{"orgOrder":0,"company":"Mabxience","sponsor":"Intas Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"SPAIN","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Etanercept","moa":"","graph1":"Immunology","graph2":"Undisclosed","graph3":"Mabxience","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Mabxience \/ Intas Pharmaceuticals","highestDevelopmentStatusID":"1","companyTruncated":"Mabxience \/ Intas Pharmaceuticals"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Sandoz B2B","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Etanercept","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Lupin Ltd \/ Sandoz B2B","highestDevelopmentStatusID":"12","companyTruncated":"Lupin Ltd \/ Sandoz B2B"}]

    Find Clinical Drug Pipeline Developments & Deals for Etanercept

    Menu

    Etanercept

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Lupin Ltd

                            India arrow
                            Antibody Engineering
                            Not Confirmed

                            Lupin Ltd

                            India arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Etanercept

                            Therapeutic Area : Immunology

                            Study Phase : Approved

                            Sponsor : Sandoz B2B

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Lupin Launches Rymti Biosimilar Etanercept in Canada

                            Details : Rymti is an etanercept-biosimilar TNF blocker indicated for treating rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis.

                            Brand Name : Rymti

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            May 03, 2024

                            Lead Product(s) : Etanercept

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved

                            Sponsor : Sandoz B2B

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Mabxience

                            Spain arrow
                            Antibody Engineering
                            Not Confirmed

                            Mabxience

                            Spain arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Etanercept

                            Therapeutic Area : Immunology

                            Study Phase : Undisclosed

                            Sponsor : Intas Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Indian firm Intas Pharma Inks New Licensing Agreement for Treating Autoimmune Diseases in 150+ Countries

                            Details : Under the agreement, Intas receives exclusive rights to commercialise Etanercept biosimilars, through its affiliates, for the treatment of various autoimmune diseases, in more than 150 countries across the globe, including Europe and the United States of...

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            December 20, 2023

                            Lead Product(s) : Etanercept

                            Therapeutic Area : Immunology

                            Highest Development Status : Undisclosed

                            Sponsor : Intas Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Sorrento Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Sorrento Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Etanercept

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : 4P Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Nutriband Subsidiary, 4P Therapeutics LLC, Conducts Phase 1b Clinical Study for Sorrento Therapeutics, Inc. on...

                            Details : The NTM device was applied to the dorsal forearm and etanercept infused for 1.25 hours. The device was alternately applied between the left and right forearms every other week.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            October 26, 2022

                            Lead Product(s) : Etanercept

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : 4P Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Samsung Bioepis

                            South Korea arrow
                            Antibody Engineering
                            Not Confirmed

                            Samsung Bioepis

                            South Korea arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Etanercept

                            Therapeutic Area : Dermatology

                            Study Phase : Approved

                            Sponsor : Samsung Biologics

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Samsung Biologics Completes Full Acquisition of Samsung Bioepis

                            Details : Upon the acquisition of Biogen’s equity stake, companies will continue their agreement, including commercialization of products BENEPALI (etanercept), a biosimilar of ENBREL, IMRALDITM (adalimumab), a biosimilar of Humira and FLIXABI (infliximab), a bi...

                            Brand Name : Benepali

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            April 20, 2022

                            Lead Product(s) : Etanercept

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved

                            Sponsor : Samsung Biologics

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Biogen

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Biogen

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Etanercept

                            Therapeutic Area : Immunology

                            Study Phase : Approved

                            Sponsor : Samsung Biologics

                            Deal Size : $2,350.0 million

                            Deal Type : Divestment

                            DEALS_DEV arrow-down

                            Biogen Reaches Agreement with Samsung Biologics to Sell Equity Stake in Their Biosimilar Joint Venture for up ...

                            Details : Upon the acquisition of Biogen’s equity stake, companies will continue their agreement, including commercialization of products BENEPALI (etanercept), a biosimilar of ENBREL, IMRALDITM (adalimumab), a biosimilar of Humira and FLIXABI (infliximab), a bi...

                            Brand Name : Benepali

                            Molecule Type : Large molecule

                            Upfront Cash : $1,000.0 million

                            January 27, 2022

                            Lead Product(s) : Etanercept

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved

                            Sponsor : Samsung Biologics

                            Deal Size : $2,350.0 million

                            Deal Type : Divestment

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Sorrento Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Sorrento Therapeutics

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Etanercept

                            Therapeutic Area : Immunology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Sorrento Publishes Positive Initial Results of SOFUSA® Lymphatic Drug Delivery System in a Phase 1b Rheumatoi...

                            Details : The first patient treated with Sofusa with Enbrel achieved a dramatic improvement in disease activity in just 12 weeks receiving only 50% of the Enbrel subcutaneous dose weekly.

                            Brand Name : Enbrel

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            August 23, 2021

                            Lead Product(s) : Etanercept

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Merck & Co

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Merck & Co

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Etanercept

                            Therapeutic Area : Dermatology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Health Canada approves Merck’s etanercept biosimilar for new indications

                            Details : BRENZYS® is a type of protein called a tumour necrosis factor (TNF) blocker that blocks the action of TNF-alpha, an Inflammatory cytokine which is over produced in people suffering from Plaque Psoriasis (PsO).

                            Brand Name : Brenzys

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            September 15, 2020

                            Lead Product(s) : Etanercept

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Viatris

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Viatris

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Etanercept

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Mylan and Lupin Announce Positive CHMP Opinion for Nepexto®, Biosimilar Etanercept

                            Details : The positive CHMP opinion is based on a biosimilarity assessment which included preclinical and clinical studies demonstrating bioequivalence to the reference product.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            March 27, 2020

                            Lead Product(s) : Etanercept

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth